In his latest article for the Association of Clinical Research Professionals (ACRP), Paul Evans outlines how integrated site organizations can pave the way for AI adoption and generate tangible value for the industry.
For sites, investigators, and patients, Gen AI has the potential to streamline recruitment, reduce manual labor, and accelerate trial processes. By leveraging large datasets and advanced language models in our VISION technology platform, we’re already beginning to reshape the way clinical trials are conducted at Velocity.
